Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors

  • M Laakso
  • Niklas Loman
  • Åke Borg
  • J Isola
Publishing year: 2005
Language: English
Pages: 1321-1328
Publication/Series: Modern Pathology
Volume: 18
Issue: 10
Document type: Journal article
Publisher: Nature Publishing Group

Abstract english

Breast ducts contain two types of epithelial cells, inner luminal cells and outer basal/ myoepithelial cells. These cells can be distinguished by their immunophenotype. Cytokeratins ( CKs) 8 and 18 are expressed in the luminal layer, whereas CK5/ 14 and the transcription factor p63 characterize the basal epithelial layer. We studied a population- based cohort of 288 sporadic ductal invasive cancers and found 9% positive for CK5/ 14 and 4% positive for p63. Using a highly sensitive polymer- based immunohistochemical staining, all sporadic tumors were positive for the luminal CK8/ 18, including those positive for CK5/ 14. Pairs of primary tumors and metastases ( n = 38) were always concordant for CK5/ 14 expression. The majority of the CK5/ 14- positive cases were of histologic grade III ( P = 0.0007) and steroid hormone receptor negative ( P < 0.0001). CK5/ 14 expression was inversely associated with HER- 2 oncogene amplification, but only in the subgroup of estrogen receptor-negative tumors ( P = 0.007). In a separate set of 42 hereditary breast cancers, the majority ( 78%) of the BRCA1-associated tumors, but only one of 15 BRCA2- associated tumors was positive for CK5/ 14. In contrast to sporadic CK5/ 14- positive tumors, BRCA1- associated tumors displayed less intense CK8/ 18 staining, including some truly CK5/ 14- positive CK8/ 18- negative cases. These results suggest that CK5/ 14- positive sporadic breast cancers arise from glandularly committed progenitor cells rather than true CK8/ 18- negative basal cells.


  • Cancer and Oncology
  • immunohistochemistry
  • HER-2
  • cytokeratin
  • BRCA2
  • basal phenotype
  • BRCA1
  • oncogene
  • progenitor cell


  • ISSN: 1530-0285
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2


Project manager

Familial Breast Cancer



Oncology and Pathology, MV

MV 404 C21C2